- Home
- CPRI vs CNTA Comparison
CPRI vs CNTA Comparison
Compare CPRI & CNTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPRI
- CNTA
- Stock Information
- Founded
- CPRI 1981
- CNTA 2020
- Country
- CPRI United Kingdom
- CNTA United Kingdom
- Employees
- CPRI N/A
- CNTA N/A
- Industry
- CPRI Apparel
- CNTA Biotechnology: Pharmaceutical Preparations
- Sector
- CPRI Consumer Discretionary
- CNTA Health Care
- Exchange
- CPRI Nasdaq
- CNTA Nasdaq
- Market Cap
- CPRI 2.0B
- CNTA 1.6B
- IPO Year
- CPRI 2011
- CNTA 2021
- Fundamental
- Price
- CPRI $18.12
- CNTA $13.51
- Analyst Decision
- CPRI Buy
- CNTA Strong Buy
- Analyst Count
- CPRI 11
- CNTA 11
- Target Price
- CPRI $22.45
- CNTA $27.00
- AVG Volume (30 Days)
- CPRI 3.3M
- CNTA 730.3K
- Earning Date
- CPRI 05-28-2025
- CNTA 05-14-2025
- Dividend Yield
- CPRI N/A
- CNTA N/A
- EPS Growth
- CPRI N/A
- CNTA N/A
- EPS
- CPRI N/A
- CNTA N/A
- Revenue
- CPRI $4,442,000,000.00
- CNTA $15,000,000.00
- Revenue This Year
- CPRI N/A
- CNTA N/A
- Revenue Next Year
- CPRI $1.18
- CNTA N/A
- P/E Ratio
- CPRI N/A
- CNTA N/A
- Revenue Growth
- CPRI N/A
- CNTA 118.88
- 52 Week Low
- CPRI $11.86
- CNTA $7.90
- 52 Week High
- CPRI $43.34
- CNTA $19.09
- Technical
- Relative Strength Index (RSI)
- CPRI 57.33
- CNTA 56.37
- Support Level
- CPRI $16.54
- CNTA $12.11
- Resistance Level
- CPRI $19.47
- CNTA $13.23
- Average True Range (ATR)
- CPRI 0.72
- CNTA 0.73
- MACD
- CPRI 0.06
- CNTA 0.12
- Stochastic Oscillator
- CPRI 53.92
- CNTA 98.13
About CPRI Capri Holdings Limited
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Michael Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 700 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. In April 2025, Capri agreed to sell Versace to Prada. John Idol has served as Capri's CEO since 2003.
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include: SerpinPC for Hemophilia A, B; LB101 for Solid Tumors; ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders; MGX292 Pulmonary Arterial Hypertension (PAH); and Undisclosed for Solid Tumors.